Ampio provides litigation update - reports settlement in principle of certain pending legal actions

Englewood, colo. , jan. 11, 2024 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe) (the "company" or "ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its oa-201 program, today announced that it has reached settlements in principle in the pending securities fraud class action, case number 22-cv-2105-wjm-meh (the "securities class action"), and the pending consolidated derivative actions in the united states district court for the district of colorado, case number 22-cv-2803-klm (the "consolidated derivative actions").
AMPE Ratings Summary
AMPE Quant Ranking